These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38250735)

  • 1. Design of protein-binding peptides with controlled binding affinity: the case of SARS-CoV-2 receptor binding domain and angiotensin-converting enzyme 2 derived peptides.
    Parisi G; Piacentini R; Incocciati A; Bonamore A; Macone A; Rupert J; Zacco E; Miotto M; Milanetti E; Tartaglia GG; Ruocco G; Boffi A; Di Rienzo L
    Front Mol Biosci; 2023; 10():1332359. PubMed ID: 38250735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Design and Experimental Validation of ACE2-Derived Peptides as SARS-CoV-2 Receptor Binding Domain Inhibitors.
    Sarma S; Herrera SM; Xiao X; Hudalla GA; Hall CK
    J Phys Chem B; 2022 Oct; 126(41):8129-8139. PubMed ID: 36219223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Design of 25-mer Peptide Binders of SARS-CoV-2.
    Sitthiyotha T; Chunsrivirot S
    J Phys Chem B; 2020 Dec; 124(48):10930-10942. PubMed ID: 33200935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor.
    Sitthiyotha T; Chunsrivirot S
    Sci Rep; 2021 Aug; 11(1):15650. PubMed ID: 34341401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.
    Pourmand S; Zareei S; Shahlaei M; Moradi S
    Comput Biol Med; 2022 Jul; 146():105625. PubMed ID: 35688710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
    Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
    J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants.
    Sang P; Chen YQ; Liu MT; Wang YT; Yue T; Li Y; Yin YR; Yang LQ
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ACE2 orthologous peptide sequences show better binding affinity to SARS-CoV-2 RBD domain: Implications for drug design.
    Mahmoudi Azar L; Öncel MM; Karaman E; Soysal LF; Fatima A; Choi SB; Eyupoglu AE; Erman B; Khan AM; Uysal S
    Comput Struct Biotechnol J; 2023; 21():4096-4109. PubMed ID: 37671240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
    Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
    Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein.
    Sarto C; Florez-Rueda S; Arrar M; Hackenberger CPR; Lauster D; Di Lella S
    Biol Chem; 2022 Apr; 403(5-6):615-624. PubMed ID: 35357791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
    Dehury B; Raina V; Misra N; Suar M
    J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions.
    Liu X; Jiang L; Li L; Lu F; Liu F
    Heliyon; 2023 Jan; 9(1):e12890. PubMed ID: 36686609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactoferrin Inhibition of the Complex Formation between ACE2 Receptor and SARS CoV-2 Recognition Binding Domain.
    Piacentini R; Centi L; Miotto M; Milanetti E; Di Rienzo L; Pitea M; Piazza P; Ruocco G; Boffi A; Parisi G
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A colorimetric sandwich-type bioassay for SARS-CoV-2 using a hACE2-based affinity peptide pair.
    Zhu Q; Zhou X
    J Hazard Mater; 2022 Mar; 425():127923. PubMed ID: 34906876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
    Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing Short Peptides to Block the Interaction of SARS-CoV-2 and Human ACE2 for COVID-19 Therapeutics.
    Basit A; Karim AM; Asif M; Ali T; Lee JH; Jeon JH; Rehman SU; Lee SH
    Front Pharmacol; 2021; 12():731828. PubMed ID: 34512357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution.
    Erausquin E; Glaser F; Fernández-Recio J; López-Sagaseta J
    Acta Crystallogr D Struct Biol; 2022 Sep; 78(Pt 9):1156-1170. PubMed ID: 36048155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.